Abstract
Objective
The main purpose of this study was to investigate the current situation of primary Sjögren’s syndrome (pSS) patients with interstitial lung disease (ILD) in China. The relationships between social demography, disease activity, psychological status, clinical variables, and ILD were analyzed. Besides that, the quality of life (QoL) in pSS with ILD was also analyzed.
Methods
In the cross-sectional study, 101 pSS patients participated in this study. Under the guidance of the researchers, the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI), EULAR Sjögren’s Syndrome Patient-Reported Index (ESSPRI), the Short-Form 36 health survey (SF-36), Hospital Anxiety and Depression Scale (HADS), Pittsburgh sleep quality index (PSQI), Summated Xerostomia Inventory (SXI), and other related questionnaires were completed. Independent sample t tests, Mann-Whitney U test, chi-square test, and correlational analysis were used.
Results
The data showed that 28 (30.1%) pSS people with ILD. The occurrence and development of ILD were associated with disease duration, fatigue, alanine aminotransferase (ALT), neutrophils, albumin, and use of hormone. The survey also found that the QoL of pSS-ILD was significantly lower than non-ILD, especially the score in the dimension of role physical function.
Conclusions
ILD was very common in pSS. ILD had a significant negative impact on the QoL of patients. Therefore, it is of great significance to strengthen the early intervention and drug treatment of pSS patients to prevent ILD and improve their QoL.
Key Points • This cross-sectional study finds that the incidence of ILD in patients with pSS is 30.1%. • The occurrence and development of ILD is associated with disease duration, fatigue, alanine aminotransferase (ALT), neutrophils, albumin, and use of hormone. •The study also finds that the QoL of pSS-ILD is significantly lower than in patients with non-ILD, especially the score in the dimension of role physical function. |
Similar content being viewed by others
References
Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Colafrancesco S, Pipi E, Kollert F, Hunter KJ, Brewer C, Buckley CD, Bowman SJ, Priori R, Valesini G, Juarez M, Fahy WA, Fisher BA, Payne A, Allen RA, Barone F (2019) Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjogren’s syndrome. Ann Rheum Dis 78(2):249–260
Lin CY, Tseng CF, Liu JM et al (2019) Association between periodontal disease and subsequent Sjogren’s syndrome: a nationwide population-based cohort study. Int J Environ Res Public Health 16(5)
Psianou K, Panagoulias I, Papanastasiou AD, de Lastic AL, Rodi M, Spantidea PI, Degn SE, Georgiou P, Mouzaki A (2018) Clinical and immunological parameters of Sjogren’s syndrome. Autoimmun Rev 17(10):1053–1064
Cui Y, Li L, Xia L, Zhao Q, Chen S, Fu T, Ji J, Gu Z (2018) The impact of disease activity and psychological status on quality of life for Chinese patients with primary Sjogren’s syndrome. Patient Prefer Adherence 12:1513–1519
Witte T (2018) Sjogren’s syndrome: early diagnosis and effective treatment[J]. Dtsch Med Wochenschr 143(24):1778–1782
Tsigalou C, Stavropoulou E, Bezirtzoglou E (2018) Current insights in microbiome shifts in Sjogren’s syndrome and possible therapeutic interventions. Front Immunol 9:1106
Price EJ, Baer AN 2019 How to treat Sjogren’s syndrome[J]. Rheumatology (Oxford)
Zibrak JD, Price D (2014) Interstitial lung disease: raising the index of suspicion in primary care. NPJ Prim Care Respir Med 24:14054
Dong X, Zhou J, Guo X, Li Y, Xu Y, Fu Q, Lu Y, Zheng Y (2018) A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjogren’s syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol 37(11):2981–2988
Roca F, Dominique S, Schmidt J, Smail A, Duhaut P, Lévesque H, Marie I (2017) Interstitial lung disease in primary Sjogren’s syndrome. Autoimmun Rev 16(1):48–54
Manfredi A, Sebastiani M, Cerri S, Cassone G, Bellini P, Casa GD, Luppi F, Ferri C (2017) Prevalence and characterization of non-sicca onset primary Sjogren syndrome with interstitial lung involvement. Clin Rheumatol 36(6):1261–1268
Bajwah S, Yorke J (2017) Palliative care and interstitial lung disease. Curr Opin Support Palliat Care 11(3):141–146
Chetta A, Marangio E, Olivieri D (2004) Pulmonary function testing in interstitial lung diseases. Respiration 71(3):209–213
Kishaba T, Mcgill R, Nei Y et al (2018) Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody. J Med Invest 65(3.4):251–257
Cottin V, Hirani NA, Hotchkin DL et al (2018) Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 27(150)
Cottin V, Wollin L, Fischer A et al (2019) Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev 28:–151
Kampolis CF, Fragkioudaki S, Mavragani CP et al (2018) Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjogren’s syndrome. Clin Exp Rheumatol 36 Suppl 112(3):94–101
Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X (2017) the International Sjögren’s Syndrome Criteria Working Group 2016 American College of Rheumatology/European league against rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 69(1):35–45
Li L, Gao S, Fu Q, Liu R, Zhang Y, Dong X, Li Y, Li M, Zheng Y (2019) A preliminary study of lung abnormalities on HRCT in patients of rheumatoid arthritis-associated interstitial lung disease with progressive fibrosis. Clin Rheumatol
Nocturne G 2019 [Sjogren’s syndrome update: clinical and therapeutic aspects][J]. Rev Med Interne
Rosas J, Sanchez-Piedra C, Fernandez-Castro M et al (2019) ESSDAI activity index of the SJOGRENSER cohort: analysis and comparison with other European cohorts. Rheumatol Int 39(6):991–999
Li Z, Fu T, Li L, Cui Y, Dong C, Li J, Gu Z (2018) Prevalence, severity, and predictors of dry eye and dry mouth in Chinese patients with primary Sjogren syndrome. Clin Rheumatol 37(11):2971–2979
He SL, Wang JH, Li M (2013) Validation of the Chinese version of the summated xerostomia inventory (SXI). Qual Life Res 22(10):2843–2847
Bollmeier SG, Seaton TL, Prosser TR et al (2003) Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting. J Am Pharm Assoc 2019
Cui Y, Xia L, Li L et al (2018) Anxiety and depression in primary Sjogren’s syndrome: a cross-sectional study. BMC Psychiatry 18(1):131
Miyamoto ST, Valim V, Fisher BA (2019) Health-related quality of life and costs in Sjogren’s syndrome. Rheumatology (Oxford)
Priori R, Minniti A, Antonazzo B et al (2016) Sleep quality in patients with primary Sjogren’s syndrome. Clin Exp Rheumatol 34(3):373–379
Haldorsen K, Bjelland I, Bolstad AI et al (2011) A five-year prospective study of fatigue in primary Sjogren’s syndrome. Arthritis Res Ther 13(5):R167
Chen MH, Chen CK, Chou HP et al (2016) Rituximab therapy in primary Sjogren’s syndrome with interstitial lung disease: a retrospective cohort study. Clin Exp Rheumatol 34(6):1077–1084
Palm O, Garen T, Berge Enger T, Jensen JL, Lund MB, Aalokken TM, Gran JT (2013) Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data. Rheumatology (Oxford) 52(1):173–179
Wang Y, Hou Z, Qiu M, Ye Q (2018) Risk factors for primary Sjogren syndrome-associated interstitial lung disease. J Thorac Dis 10(4):2108–2117
Kakugawa T, Sakamoto N, Ishimoto H, Shimizu T, Nakamura H, Nawata A, Ito C, Sato S, Hanaka T, Oda K, Kido T, Miyamura T, Nakashima S, Aoki T, Nakamichi S, Obase Y, Saito K, Yatera K, Ishimatsu Y, Nakayama T, Korogi Y, Kawakami A, Tanaka Y, Mukae H (2018) Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjogren’s syndrome. Respir Med 137:95–102
Gao H, Zhang XW, He J, Zhang J, An Y, Sun Y, Jia RL, Li SG, Zhang LJ, Li ZG (2018) Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjogren syndrome patients: a case-control study. Medicine (Baltimore) 97(24):e11003
Yazisiz V, Arslan G, Ozbudak IH, Turker S, Erbasan F, Avci AB, Ozbudak O, Terzioglu E (2010) Lung involvement in patients with primary Sjogren’s syndrome: what are the predictors? Rheumatol Int 30(10):1317–1324
O’neill ID, Scully C (2013) Biologics in oral medicine: Sjogren syndrome. Oral Dis 19(2):121–127
Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M (2019) Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J:1900161
Hartung W, Maier J, Pfeifer M et al (2012) Effective treatment of rheumatoid arthritis-associated interstitial lung disease by B-cell targeted therapy with rituximab. Case Reports Immunol 2012:272303
Natalini JG, Swigris JJ, Morisset J, Elicker BM, Jones KD, Fischer A, Collard HR, Lee JS (2017) Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. Respir Med 127:1–6
Acknowledgments
The authors want to thank Wei Zhou, Jiaxin Guo, Mei He Ping Li, and Jianlin Gao for their assistance with this paper.
Funding
This work was supported by the Postgraduate Research and Practice Innovation Program of Jiangsu Province (grant number KYCX19-2071), National Natural Science Foundation of China (grant number 81671616 and 81871278), Science and technology Project of Jiangsu Province (grant number BE2018671), and Research Center of Gerontology and Longevity, Affiliated Hospital of Nantong University, Nantong (grant number HS2018004).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
The Ethics Committee of the Affiliated Hospital of Nantong University approved this study (ethics approval number: 2017-K003).
All participants obtained informed consent in the study.
Disclosures
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhao, R., Wang, Y., Zhou, W. et al. Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren’s syndrome. Clin Rheumatol 39, 483–489 (2020). https://doi.org/10.1007/s10067-019-04753-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-019-04753-5